2013 Annual Meeting | Multiple Sclerosis Overview II: Clinical Advances

Date Friday 03/22/13

Time 01:00 PM - 05:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Mark S. Freedman, MD, FAAN

Topic(s)

Learning Objectives Participants should become familiar with key clinical concepts in multiple sclerosis regarding how to diagnose, monitor, and treat patients with multiple sclerosis, apply MRI in assessment of multiple sclerosis, recent critical breakthroughs in MS disease-modifying therapies and symptom management.

CME Available No CME available

Core Competencies Practice-based Learning and Improvement

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
01:00 PM - 01:45 PM		Making an Accurate Diagnosis of MS: What Are the Mimics You Don't Want to Miss? Heather J. MacLean, MD
01:45 PM - 02:00 PM		Questions and Answers Heather J. MacLean, MD
02:00 PM - 02:45 PM		Use and Misuse of MRI to Monitor Disease Activity: What Are the Reliable Metrics? Lael Stone, MD
02:45 PM - 03:00 PM		Questions and Answers Lael Stone, MD
03:00 PM - 03:15 PM		Break
03:15 PM - 04:00 PM		Approach to Initiating and Switching Disease-modifying Therapies: Use of Newer and Older Agents Mark S. Freedman, MD, FAAN
04:00 PM - 04:15 PM		Questions and Answers Mark S. Freedman, MD, FAAN
04:15 PM - 04:45 PM		The 'Big Leagues' of MS Symptom Management: Real Neurologists Do 'Heads and Tails' Elliot M. Frohman, MD, FAAN
04:45 PM - 05:00 PM		Questions and Answers Elliot M. Frohman, MD, FAAN

Faculty Disclosures
Mark S. Freedman, MD, FAAN	Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Actelion(Janssen/J&J). Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BiogenIdec. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS/Celgene. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Inc. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Actelion (Janssen/J&J). Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Atara Biotherapeutics. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer Healthcare. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BiogenIdec. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Clene Nanomedicine. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRI Bio. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Magenta Therapeutics. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. The institution of Dr. Freedman has received research support from Sanofi Genzyme.
Heather J. MacLean, MD	No disclosure on file
Elliot M. Frohman, MD, FAAN	Dr. Frohman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Janssen. Dr. Frohman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Janssen. Dr. Frohman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Up To Date. Dr. Frohman has received publishing royalties from a publication relating to health care.
Lael Stone, MD	No disclosure on file

��ɫ��

��ɫ��